Invasive fungal infections represent a continuous and serious threat to human health and they are associated with at least 1.5 million deaths worldwide each year. Such infections are prevalent in immunocompromised patients as a result of aggressive therapies and immunosuppressive infections such as HIV/AIDS. About 90% of these deaths are caused by species belonging to genera of fungi Candida, Aspergillus, Cryptococcus, Pneumocystis, Mucor and Rhizopus. In comparison with the development of new antibacterial drugs, antifungal drug development is more challenging because fungi are eukaryotes and many potential targets for therapy are also found in humans with substantial host toxicity risk.
Based on their targets for antifungal therapy antifungal agents can be classified in the following groups: inhibitors of ergosterol biosynthesis, fungal membrane disruptors, fungal cell wall synthesis, sphingolipids biosynthesis, nucleic acid synthesis, protein biosynthesis, microtubules biosynthesis inhibitors. 
 S. Campoy and J. L. Adrio, “Antifungals,” Biochem. Pharmacol., vol. 133, pp. 86–96, 2017, doi: 10.1016/j.bcp.2016.11.019.
Medicinal and Computational Chemistry Dept., ChemDiv, Inc.
12760 High Bluff Dr, San Diego, CA, 92130
Phone: + 1 916 234 0888
Fax: +1 858 794 4931
You can buy this library or customize your own library from our discovery collection of 1 600 000 compounds and 60 000 building blocks.